Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model. Bone samples from 35 patients with ONJ were analyzed. Control samples were taken from five patients with osteomyelitis (OM), ten patients with osteoradionecrosis, seven patients with osteoporosis and bisphosphonate medication without signs of ONJ, and six osteoporotic elderly patients. Samples were examined using scanning electron microscopy. In 54% of the bone samples of patients with ONJ, microcracks were seen. Inflammatory and connective tissue reactions within the microcracks were evident in 82% of the cases, indicating that these cracks were not artificial. In contrast, only 29% of samples from patients with oral bisphosphonate medication without ONJ, no sample from patients with OM, none of the osteoradionecrosis group, and only 17% from patients with osteoporosis showed microcracks. Statistically significant differences could be found between the ONJ group and the group after irradiation and the group with OM, respectively. The evidence of microcracks could be a first step in the pathogenesis of bisphosphonate-related ONJ. The accumulation of these microcracks leads to a situation that could be named "non-symptomatic ONJ". Disruptions of the mucosal integrity may then allow bacterial invasion, leading to jawbone infection with exposed bone, fistulas, and pain. This state could be called "symptomatic ONJ". Furthermore, an assumed local immunosuppression as indicated by various studies could explain the severe courses of therapy-resistant ONJ as regularly observed.
Hoefert
Sebastian
S
Department of Oral and Maxillofacial Surgery, Knappschaftskrankenhaus, Academic Teaching Hospital of the Ruhr-Universität Bochum, Dorstener Str 151, 45657 Recklinghausen, Germany. hoefert.sebastian@kk-recklinghausen.de
Schmitz
Inge
I
Tannapfel
Andrea
A
Eufinger
Harald
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D003238:Connective Tissue / Q000473:pathology; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007249:Inflammation / Q000473:pathology; D007568:Jaw / Q000187:drug effects / Q000648:ultrastructure*; D007571:Jaw Diseases / Q000139:chemically induced / Q000473:pathology*; D008297:Male; D008336:Mandibular Diseases / Q000473:pathology; D008439:Maxillary Diseases / Q000473:pathology; D008855:Microscopy, Electron, Scanning; D008875:Middle Aged; D010019:Osteomyelitis / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced / Q000473:pathology*; D010024:Osteoporosis / Q000473:pathology; D010025:Osteoradionecrosis / Q000473:pathology; D000077268:Pamidronate; D013997:Time Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate; D019386:Alendronate